Research To Practice | Oncology Videos Breast Cancer — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute
Nov 10, 2025
Dr Rita Nanda, expert in endocrine-resistant HR+ disease and targeted agents. Dr Harold J. Burstein, HER2 specialist with expertise in neoadjuvant and metastatic strategies. Dr Heather McArthur, authority on triple-negative disease and ADCs. Dr Matthew P. Goetz, investigator in HR+ and CDK4/6 research. They discuss genomic assays, sequencing of CDK4/6 and PI3K/AKT agents, ADC selection and toxicities, HER2 strategies, and ctDNA applications.
AI Snips
Chapters
Transcript
Episode notes
Oncotype Guidance Holds With Long-Term Data
- Long-term follow-up confirms Oncotype-guided omission of chemo remains valid for many ER+ node-negative patients.
- Clinical risk and menopausal status modify benefit, so combine genomic score with tumor size/grade when deciding.
Address Ovarian Function Before Prescribing Chemo
- Consider ovarian suppression plus an AI for premenopausal higher-risk ER+ patients instead of assuming chemo is the only option.
- Discuss the NRG009 trial context when counseling about chemo benefit uncertainty in 11–25 recurrence scores.
Adjuvant CDK4/6 Benefits Are Trial-Dependent
- Adjuvant CDK4/6 inhibitors show IDFS benefit in selected high-risk patients but OS data are immature.
- MonarchE (abemaciclib) and NATALIE (ribociclib) enrolled different high-risk cohorts so results aren't directly interchangeable.